Manoj J. Monga, MD, FACS, presented “Point-Counterpoint: Mini-PCNL vs. Standard PCNL – Standard PCNL” during the 30th Annual Perspectives in Urology: Point-Counterpoint, on March 10, 2023, at Humphreys Half Moon Inn, San Diego, California.
How to cite: Monga, Manoj J. “Point-Counterpoint: Mini-PCNL vs. Standard PCNL – Standard PCNL.” March 10, 2023. Accessed Mar 2026. https://grandroundsinurology.com/point-counterpoint-mini-pcnl-vs-standard-pcnl-standard-pcnl/
Point-Counterpoint: Mini-PCNL vs. Standard PCNL – Standard PCNL – Summary
Manoj J. Monga, MD, FACS, compares mini percutaneous nephrolithotomy (mini-PCNL) for renal stone removal to standard percutaneous nephrolithotomy (PCNL). He discusses the different risks and benefits of mini-PCNL versus standard, finding in favor of the more reliable and less expensive standard PCNL.
In this presentation, Dr. Monga discusses:
- The history of Mini-PCNL and Standard PCNL
- Increased sepsis and other infection risk in Mini-PCNL patients
- Which variables are predictive of post-operative success
This lecture is part of a Point-Counterpoint debate. Its opposing lecture is “Point-Counterpoint: Mini-PCNL vs. Standard PCNL – Mini-PCNL.”
About the 30th Annual Perspectives in Urology: Point Counterpoint conference: Presented by Program Chair and Grand Rounds in Urology Editor-in-Chief E. David Crawford, MD, this conference brought together leading experts in urology, medical oncology, and radiation oncology to discuss and debate the latest topics in genitourinary cancers, primarily prostate cancer and bladder cancer. This interactive conference offered topical lectures, pro/con debates, interesting-case presentations, interactive panel discussions, and interactive audience and faculty networking.
ABOUT THE AUTHOR
Manoj J. Monga, MD, FACS, FRCS, is a Professor and the Chair of the Department of Urology at the University of California, San Diego, where he oversees the department’s research, teaching, and clinical care. He is recognized as an international authority in endourology (minimally invasive urologic surgery) and kidney stone disease. His clinical expertise includes kidney stone prevention, medical and surgical management of kidney stone disease, and endoscopic management of upper tract transitional cell cancer and benign strictures.
